RA Capital Healthcare Fund LP 4

What Happened RA Capital Management, L.P. (the Adviser), an investment manager with a partner serving on Evommune’s board, reported an acquisition/award of 35,868 shares of Evommune (EVMN) on Feb 17, 2026. The shares were reported at $27.88 each, for a total value of $1,000,000. The transaction code is "A" (award/grant or other acquisition) — this is an acquisition of stock, not a sale.

Key Details

• Transaction date: 2026-02-17
• Shares acquired: 35,868 at $27.88 per share (total value $1,000,000)
• Transaction code: A (award/grant/other acquisition)
• Shares owned after transaction: not disclosed in the filing
• Footnotes: F1–F3 disclose that the Adviser is investment manager for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P.; the reported securities are held directly by those funds and various parties disclaim beneficial ownership except for pecuniary interest.
• Insider relationship: Dr. Derek DiRocco, a Partner of the Adviser, serves on Evommune’s board of directors (noted in Remarks).
• Filing timeliness: Reported for the same date as the transaction (no late filing indicated).

Context This filing reports an institutional acquisition by the Adviser on behalf of its funds, not a direct personal purchase by an individual executive. The filing’s footnotes emphasize the adviser/fund structure and disclaim broader beneficial ownership beyond pecuniary interest. The form does not state the purpose of the award (e.g., compensation vs. investment), and it does not show subsequent sales or transfers. For retail investors, purchases/awards by funds or adviser-affiliated entities can be informative, but the filing alone does not explain motivation.